Articles |
but Not Interleukin-1 or Basic Fibroblast Growth Factor
From the Department of Thoracic and Cardiovascular Surgery (H.T.), Tokyo Medical and Dental University, Japan, and the Vascular Medicine and Atherosclerosis Unit (G.S., D.S., P.L.), and the Cardiovascular Division (D.S., P.L.), Department of Medicine, Brigham and Women's Hospital, Boston, Mass.
Correspondence to Dr Peter Libby, Vascular Medicine and Atherosclerosis Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Longwood Medical Research Center, Room 307, 221 Longwood Ave, Boston, MA 02115.
| Abstract |
|---|
|
|
|---|
(TNF-
) and
interleukin-1ß (IL-1ß), proinflammatory and SMC
growthpromoting cytokines, and basic fibroblast growth
factor (bFGF) in SMCs of rabbit aorta at 2 (n=4), 5 (n=4), and
10 days
(n=6) after balloon injury. All animals were given bromodeoxyuridine
(BrdU, 10 mg/kg per day) continuously to label proliferating SMCs.
Frozen cross sections of injured vessels at each time point after
balloon injury were examined by immunoperoxidase staining with
monoclonal antibodies. As early as 2 days after injury, before intimal
thickening begins, foci of medial SMCs expressed TNF-
, but not all
TNF-
positive medial SMCs had incorporated BrdU, suggesting
that TNF-
expression by medial SMCs may precede their proliferation.
At 5 days, TNF-
bearing and BrdU-labeled medial SMCs increased
in number. At 10 days after injury, when uniform intimal thickening
occurred, almost all neointimal SMCs and foci of medial
SMCs labeled with BrdU. Most of the BrdU-positive (proliferating) SMCs
expressed immunoreactive TNF-
. Reverse transcription polymerase
chain reaction showed increased TNF-
mRNA at 10 days after
ballooning in the injured portion of the aorta. In contrast, regions of
SMC proliferation showed inconsistent IL-1ß expression,
and bFGF, abundant in normal rabbit arteries, was not detected in areas
of SMC replication. These data indicate that replication of
arterial SMCs after balloon injury occurs in regions of
TNF-
but not IL-1ß expression and correlates inversely with the
presence of bFGF. These results indicate that SMC-derived TNF-
serves as a marker of modulated SMC phenotype after acute
vascular injury and may contribute to local cellular activation and
proliferation of SMCs at sites of arterial injury.
Key Words: smooth muscle cells tumor necrosis factor
balloon injury proliferation
| Introduction |
|---|
|
|
|---|
Originally, the macrophage was considered the principal cell
type capable of producing TNF-
. Some years ago, our laboratory
characterized the ability of SMCs to express the gene encoding
TNF-
.10 We demonstrated this capacity at the level of
mRNA induction, de novo protein synthesis, and elaboration of
biologically active TNF by these human cells. Barath and
colleagues22 23 demonstrated that advanced human
atherosclerotic lesions contain TNF, a further indication of the
involvement of this cytokine in intimal
pathology.22 23 Because of these manifold effects of
TNF
on functions of vascular cells including those expressed after balloon
injury, the present study explored the possibility that
arterial balloon injury induced the expression of this
cytokine. This study also evaluated in parallel bFGF and IL-1,
two other protein mediators that might participate in vascular SMC
growth control.
| Methods |
|---|
|
|
|---|
BrdU Labeling of Cells
BrdU, a thymidine analogue that is
incorporated into the DNA of
S-phase proliferating cells, was continuously infused subcutaneously
through a miniaturized osmotic pump (Model 2ML-1, Alza Corp) implanted
in an anterior lower abdominal subcutaneous pocket during the same
anesthetic procedure as balloon injury. BrdU solutions were prepared in
sterile Na2CO3/NaHCO3 buffer
(0.5 mol/L, pH 9.8). The concentration of BrdU was adjusted to 250
mg/mL to release 10 mg/kg per day of the labeling agent.
Harvest and Preparation of Tissue
At 2 days (n=4), 5
days (n=4), and 10 days (n=6) after surgery,
animals were placed in a restraining cage and Evans blue (20
mg · mL saline-1 · kg-1) was
injected
via an ear vein 20 minutes before euthanasia by infusion of
pentobarbital (120 mg/kg IV). Evans blue staining clearly defined the
injured area, and the infrarenal aorta was immediately excised and
gently trimmed in Dulbecco's PBS. We prepared cross sections from the
center of the injured aorta as defined by Evans blue staining for
immunohistochemical evaluation by snap-freezing in isopentane
cooled in liquid nitrogen.
Antibodies
The following mAb were used for
immunohistochemical
analysis: mouse mAb anti-human TNF-
(a mouse
IgG1, purchased from UBI) and IL-1ß (a mouse
IgG1 purchased from Genzyme) antibody were used to
recognize the respective rabbit cytokines. An anti-human
bFGF antibody (a mouse IgG1 purchased from UBI) was used to
visualize the rabbit protein. mAb HHF-35 (mouse
IgG1, purchased from Enzo Diagnostics
Inc) recognizes muscle-specific actin.24 We detected
BrdU in cells undergoing proliferation by using mAb against BrdU (mouse
IgG1, purchased from DAKO Corp).
Immunocytochemistry
Serial cryostat sections (6 µm) were
cut, air dried onto
poly-L-lysinecoated slides, and fixed in acetone at
-20°C for 5 minutes. Sections were preincubated with PBS containing
0.3% hydrogen peroxide to reduce endogenous peroxidase
activity. The sections then were incubated with primary antibodies and
diluted in PBS with 10% horse serum at room temperature for 60
minutes. After three washes in Tris-buffered saline containing 2%
horse serum, species-appropriate biotinylated secondary antibodies
were applied followed by avidin-biotin horseradish peroxidase
complex (Vectastain ABC kit, PK 6100, Vector Laboratories). Antibody
binding was visualized with 3-amino-9-ethylcarbazole (Sigma Chemical
Co). For BrdU labeling, sections were incubated in 2 mol/L HCl at
37°C for 10 minutes to denature DNA before the addition of the
primary antibody. Sections were counterstained with Gill's
hematoxylin. Omission of primary antibodies and the staining with type-
and class-matched irrelevant immunoglobulin served as negative
control for each antibody.
For evaluation of the kinetics of SMC proliferation after balloon withdrawal injury in this model, all BrdU-labeled cells were counted separately in the intima and media of cross sections from each animal. Results are expressed as mean±SD. ANOVA was used to determine the significance of differences by comparing different time points. Differences were considered significant when P<.05.
Double Immunohistochemical Analysis
To evaluate distribution
of positive staining for both BrdU and
TNF-
in the injured area at 2 and 5 days after balloon injury, we
performed double immunohistochemistry. After staining for TNF-
using
the peroxidase ABC method described above (yielding a red peroxidase
reaction product), sections were washed in PBS for 5 minutes, and
avidin-biotin complex remaining from the first step was blocked by
incubating sections with an excess of avidin and biotin (Avidin-Biotin
blocking kit, Vector Laboratories). After the application of the
primary antibody against BrdU at 4°C overnight, sections were
incubated with biotinylated horse anti-goat antibody for 45 minutes
at room temperature. Sections were then incubated in alkaline
phosphataseavidin-biotin complex (Vectastain ABC kit,
AK-5000, Vector Laboratories) and visualized using fast blue (Sigma
Chemical Co), an alkaline phosphate substrate that produced a blue
product. Sections were counterstained with methyl green.
Double-stained cells showed red (TNF-
) and blue (BrdU)
staining.
Immunohistochemical Staining of TNF-
in Cultured Rabbit Aortic
SMCs Stimulated With Bacterial
Lipopolysaccharide
We previously reported that bacterial LPS treatment
increases
TNF-
expression in rabbit aorta.24 Therefore, we
explored the ability of the mAb against human TNF-
to recognize
rabbit TNF-
protein by study of LPS-treated SMCs cultured from
rabbit aorta by standard explant outgrowth techniques. Cultured SMCs
were treated with LPS (10 ng/mL) for 24 hours. After stimulation, SMC
monolayers were rinsed twice with PBS and immediately fixed for 1
minute in acetone at -20°C. SMCs with or without LPS treatment were
stained immunohistochemically as described above.
PCR Analysis of TNF-
mRNA in Uninjured and Injured
Rabbit Aortic Tissue
Five additional New Zealand White rabbits were
studied to
evaluate the mRNA levels of TNF-
in the uninjured and injured aorta.
The whole infrarenal abdominal aorta was injured by using the same
procedure described above. After injection of a lethal dose of sodium
pentobarbital (120 mg/kg IV) 10 days after balloon injury, the
uninjured thoracic aorta and injured infrarenal abdominal aorta were
removed from each rabbit, rinsed in sterile saline, trimmed of
adventitial tissue, and immediately frozen in liquid nitrogen. RNA
samples prepared from the spleen of LPS-treated animals served as a
positive control for the PCR analysis. Specimens of aorta and
spleen were homogenized in guanidinium isothiocyanate, and
total RNA was isolated by differential centrifugation.
One microgram of RNA was reverse-transcribed, and cDNA was
analyzed by PCR at 35 cycles, a level of amplification
previously determined to lie within the exponential range of expansion
with these primers and rabbit cDNA. Details of the PCR technique and
primers used to detect a rabbit TNF-
message have been previously
described.24 25 Seven microliters of the PCR product
was mixed with 3 µL of running buffer (orange G dye in 50% Ficoll).
This mixture was electrophoresed on a 3% agarose gel containing
ethidium bromide and visualized by ultraviolet light.
| Results |
|---|
|
|
|---|
in Cultured Rabbit SMCs Stimulated With
Bacterial LPS
protein.
|
Kinetics of SMC Proliferation at 2, 5, and 10 Days After
Balloon Injury
At 2 days after balloon injury, the intima had not
begun to
thicken, but within the tunica media of injured regions some SMCs
(96±33 per cross section, mean±SD, n=4) had proliferated
as indicated
by BrdU staining (Fig 2
, Table
). Five
days after balloon withdrawal, the intima of injured zones usually
contained one to three layers of SMCs, many of which had proliferated
(Fig 2
, Table
). At this time, BrdU labeling of
medial SMCs had
increased almost sevenfold. The extent of medial SMC proliferation
varied both from animal to animal (as indicated by the wide standard
deviation; see the Table
) and within ballooned areas within a
given
animal. This inhomogeneity in localization of BrdU+ SMCs
within the media may result from uneven distribution of the mechanical
injury to the aortic wall produced by the withdrawal of the inflated
balloon catheter. At 10 days after balloon injury, the expanding intima
consisted of 5 to 15 layers of SMCs, of which many had proliferated
during the 10-day labeling period with BrdU (1061±469 per cross
section, n=6, Table
).
|
|
Expression of TNF-
in Medial SMCs 2 and 5 Days After
Balloon Injury
At 2 days after injury, SMC proliferation detected by
BrdU
staining was limited to the portion of the media just below the
internal elastic lamina. The area of TNF-
expression coincided with
this area (Fig 2
). Double immunohistochemical staining revealed
many
medial SMCs that had not divided (BrdU-), surrounded by
SMCs that had proliferated during the labeling period
(BrdU+) (Fig 3
). This result could indicate
that expression of TNF-
precedes SMC proliferation, as many of the
SMCs in this region will go on to divide during the subsequent 3 days
(Table
). At 5 days after injury, many medial SMCs had
incorporated
BrdU, although the extent of medial SMC proliferation varied among
regions of the injured media (Fig 3
). As noted above, this
irregular
localization of BrdU+ SMCs in the media may result from
inhomogeneous or noncircumferential distribution of
mechanical injury to the aortic wall produced by balloon withdrawal.
The proliferating medial SMCs clearly colocalized with immunoreactive
TNF-
(Fig 3
) although some
BrdU-/TNF+ SMCs localized within and
surrounding dense foci of BrdU+ SMCs. At 5 days after
balloon injury, a population of medial SMCs surrounding dense foci of
BrdU+ SMCs expressed TNF-
(Fig 3
).
|
Expression of TNF-
, IL-1ß, and bFGF in Neointimal
and Medial SMCs 10 Days After Balloon Injury
Normal portions of the
aorta proximal to the site of injury showed
no immunoreactive TNF-
, abundant bFGF associated with medial SMCs as
previously reported in rat and human arteries,5 26
and
some IL-1ß localized to the endothelium (Fig 4
). In the
injured zone 10 days after balloon injury,
the neointima consisted of 5 to 15 layers of SMCs, most of
which had undergone division during 10 days after injury as determined
by BrdU incorporation (Fig 4
). Most of these neointimal
SMCs expressed TNF-
. Medial SMCs incorporated BrdU and those SMCs
that had proliferated (BrdU+) also stained for TNF-
(Fig
4
). In contrast, staining for bFGF in the neointima was
much lower than in the underlying media of the injured segment or of
the uninjured portion of the same vessel (Fig 4
), as previously
seen in
the rat.5 Neither the media nor intima showed appreciable
IL-1ß staining (Fig 4
). The antibody used in this study
does
recognize this cytokine in SMCs and endothelial
cells in the aortas of rabbits fed an atherogenic diet,27
and preabsorption of this antibody with recombinant human IL-1ß
reduced this immunoreactivity (data not shown).
|
Increased TNF-
mRNA in the Injured Aorta
We analyzed RNA
extracted from a rabbit aorta 10 days
after balloon injury for TNF-
message by reverse transcriptase-PCR
analysis. The uninjured aorta contained little or no TNF
message detectable by this technique. However, the signal corresponding
to the PCR product from the injured zone of the aorta formed an
intense ethidium bromidestained band after 35 cycles of PCR
amplification (Fig 5
). This increase of TNF-
message
in the injured portion of aorta was consistent in five of five
rabbits studied. This PCR product comigrated with that amplified
from RNA from the spleen of an LPS-treated rabbit used as positive
control and corresponded to the expected product based on the
primers chosen and the sequence of rabbit TNF-
.
|
| Discussion |
|---|
|
|
|---|
mRNA and protein expression by
arterial SMCs. McKeehan and colleagues11 and
our laboratory12 have presented evidence that
exposure to TNF stimulates SMCs to divide. Thus, locally produced TNF
might contribute to SMC proliferation after arterial
injury. However, TNF-
itself may not suffice to initiate
mitogenesis, as other signals or comitogens might be required for a
TNF-producing SMC to undergo division. For example, TNF can regulate
the expression of FGF, platelet-derived growth factor, and
heparin-binding epidermal growth factorlike
molecule.13 14 15
Barath et al22 23 reported that neointimal
cells (primarily SMCs) in human atheromatous plaque
expressed TNF-
and TNF mRNA, whereas the medial SMCs do not.
Neointimal SMCs in atheromatous plaque may
represent a modulated phenotype of
SMC.28 29 We observed here expression of TNF-
not only
in neointimal SMCs but also in proliferating medial SMCs
and some BrdU- medial SMCs surrounding dense areas of
BrdU+ SMCs. Some of these
TNF-
+/BrdU- SMCs may later
proliferate or migrate into the intima. Thus, SMC-derived TNF-
may
furnish one signal that contributes to phenotypic modulation and
proliferation of SMCs after balloon injury. Our data and those from
Reidy's laboratory obtained in the rat5 show much lower
levels of immunoreactive bFGF in the neointima after injury
than in normal arterial media, suggesting that this growth
factor does not contribute to ongoing proliferation of
neointimal SMCs. The weak and inconsistent
localization of IL-1ß in the injured artery does not support a role
for this potential growth stimulus in this process
either.30
Although proof of a growth-promoting effect of TNF in vivo is
lacking, our data establish SMC TNF expression as a novel marker for
SMC activation in response to injury. Smooth musclederived TNF,
if biologically available to neighboring cells, might also enhance
nonmitogenic aspects of SMC activation by paracrine or
autocrine effects. For example, TNF can increase intercellular adhesion
molecule-1 expression by vascular SMCs.9 The expression of
this adhesion molecule by SMCs in human
atheroma31 32 and in hyperplastic lesions
produced by experimental balloon injury1 indicates that
augmented intercellular adhesion molecule-1 expression constitutes a
marker of SMC activation of considerable in vivo relevance. In
addition, TNF, perhaps in conjunction with other cytokines such
as interferon-
, may promote the expression of the inducible form of
NO synthase. This enzyme catalyzes the production of the
multipotent vascular mediator NO. Recent evidence indicates that
balloon injury can induce the expression of an activity that resembles
inducible NO synthase in the rat carotid artery.30 Hence,
TNF may function as an inducer of this important enzyme as well.
Certain strategies for interfering with TNF action in vivo are becoming
available.33 For example, soluble TNF receptors, anti-TNF
antibodies, and other similar agents might be used to test critically
the function of TNF induced in SMCs by balloon injury. Clausell and
colleagues33 have used this approach to demonstrate
possible involvement of TNF-
in intimal thickening in the
coronary arteries of transplanted hearts. To our knowledge,
none have yet characterized the pharmacokinetics of any of these
reagents in rabbits. Furthermore, rabbits promptly mount a humoral
immune response to foreign proteins. As antigen-antibody complexes
can readily enhance intimal lesion formation in this species,
administration of foreign proteins may yield unclear
results.34 Additionally, achievable local concentrations
of exogenously administered neutralizing agents may not prove
sufficient to inhibit intracrine or paracrine signaling loops mediated
by contact via cell surfaceassociated forms of TNF. Our
present results, however, encourage the exploration of these or
other strategies to elucidate the in vivo roles of TNF in vascular
pathology. Such modalities might also provide avenues for local therapy
in the future. The data presented here provide new evidence for
sustained activation of SMCs after balloon injury in vivo and furnish
further support for the concept that ongoing inflammatory processes
participate in the vascular response to injury.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received March 25, 1995; accepted September 11, 1995.
| References |
|---|
|
|
|---|
2. Lindner V, Majack RA, Reidy MA. Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest. 1990;85:2004-2008.
3.
Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA.
Role of basic fibroblast growth factor in vascular lesion
formation. Circ Res. 1991;68:106-113.
4.
Lindner V, Reidy MA. Proliferation of smooth
muscle cells after vascular injury is inhibited by an antibody against
basic fibroblast growth factor. Proc Natl Acad Sci
U S A. 1991;88:3739-3743.
5. Olson NE, Chao S, Lindner V, Reidy MA. Intimal smooth muscle cell proliferation after balloon catheter injury: the role of basic fibroblast growth factor. Am J Pathol. 1992;140:1017-1023. [Abstract]
6.
Libby P, Goldberg AL. Leupeptin, a protease
inhibitor, decreases protein degradation in normal and
diseased muscles. Science. 1978;199:534-536.
7. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 1992;86(suppl III):III-47-III-52.
8. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5-15. [Medline] [Order article via Infotrieve]
9.
Couffinhal T, Duplaa C, Labat L, Lamaziere JM, Moreau
C, Printseva O, Bonnet J. Tumor necrosis factor-alpha
stimulates ICAM-1 expression in human vascular smooth muscle
cells. Arterioscler Thromb. 1993;13:407-414.
10. Warner SJC, Libby P. Human vascular smooth muscle cells: target for and source of tumor necrosis factor. J Immunol. 1989;142:100-109. [Abstract]
11. Sawada H, Kan M, McKeehan WL. Opposite effects of monokines (interleukin-1, and tumor necrosis factor) on proliferation and heparin-binding (fibroblast) growth factor binding to human aortic endothelial and smooth muscle cells. In Vitro Cell Dev Biol. 1990;26:213-216. [Medline] [Order article via Infotrieve]
12. Palmer H, Libby P. Interferon-beta: a potential autocrine regulator of human vascular smooth muscle cell growth. Lab Invest. 1992;66:715-721. [Medline] [Order article via Infotrieve]
13.
Vilcek J, Palombella VJ, Henriksen-DeStefano D, Swenson
C, Feinman R, Hirai M, Tsujimoto M. Fibroblast growth enhancing
activity of tumor necrosis factor and its relationship to other
polypeptide growth factors. J Exp Med. 1986;163:632-643.
14.
Hajjar KA, Hajjar DP, Silverstein RL, Nachman RL.
Tumor necrosis factor-mediated release of
platelet-derived growth factor from cultured
endothelial cells. J Exp
Med. 1987;166:235-245.
15.
Yoshizumi M, Kourembanas S, Temizer DH, Cambria RP,
Quertermous T, Lee ME. Tumor necrosis factor increases
transcription of the heparin-binding epidermal growth
factor-like growth factor gene in vascular
endothelial cells. J Biol
Chem. 1992;267:9467-9469.
16.
Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L,
Stern D. Tumor necrosis factor/cachectin interacts with
endothelial cell receptors to induce release of
interleukin 1. J Exp Med. 1986;163:1363-1375.
17. Pober JS, Gimbrone MAJ, Lapierre LA, Mendrick DL, Fiers W, Rothlein R, Springer TA. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol. 1986;137:1893-1896. [Abstract]
18.
Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS,
Gimbrone MAJ. Recombinant tumor necrosis factor induces
procoagulant activity in cultured human vascular
endothelium: characterization and comparison with the
actions of interleukin 1. Proc Natl Acad Sci
U S A. 1986;83:4533-4537.
19. Cybulsky MI, Chan MKW, Movat HZ. Acute inflammation and microthrombosis induced by endotoxin, interleukin-1 and tumor necrosis factor and their implication in gram-negative infection. Lab Invest. 1988;58:365-378. [Medline] [Order article via Infotrieve]
20. Cybulsky MI, McComb DJ, Movat HZ. Neutrophil leukocyte emigration induced by endotoxin: mediator roles of interleukin 1 and tumor necrosis factor a1. J Immunol. 1988;140:3144-3149. [Abstract]
21.
Carlos TM, Schwartz BR, Kovach NL, Yee E, Rosa M,
Osborn L, Chi-Rosso G, Newman B, Lobb R, Rosso M, Harlan J.
Vascular cell adhesion molecule-1 mediates lymphocyte adherence
to cytokine-activated cultured human
endothelial cells. Blood. 1990;76:965-970.
22. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol. 1990;65:297-302. [Medline] [Order article via Infotrieve]
23. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Tumor necrosis factor gene expression in human vascular intimal smooth muscle cells detected by in situ hybridization. Am J Pathol. 1990;137:503-509. [Abstract]
24. Fleet JC, Clinton SK, Salomon RN, Loppnow H, Libby P. Atherogenic diets enhance endotoxin-stimulated interleukin-1 and tumor necrosis factor gene expression in rabbit aortae. J Nutr. 1992;122:294-305.
25.
Salomon RN, Underwood R, Doyle MV, Wang A, Libby P.
Increased apolipoprotein E and c-fms gene expression without
elevated interleukin 1 or 6 levels indicate selective activation of
macrophage functions in advanced human
atheroma. Proc Natl Acad Sci U S A. 1992;89:2814-2818.
26. Brogi E, Winkles J, Underwood R, Clinton S, Alberts G, Libby P. Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and non-atherosclerotic arteries: association of acidic FGF with plaque microvessels and macrophages. J Clin Invest. 1993;92:2408-2418.
27.
Tanaka H, Sukhova G, Libby P. Interaction of the
allogeneic state and hypercholesterolemia in
arterial lesion formation in experimental cardiac
allografts. Arterioscler Thromb. 1994;14:734-745.
28. Campbell GR, Campbell JH, Ang AH, Campbell IL, Horrigan S, Manderson JA, Mosse PRL, Newman RE. Phenotypic changes in smooth muscle cells of human atherosclerotic plaques. In: Glagov S, Newman WPI, Schaffer SA, eds. Pathobiology of the Human Atherosclerotic Plaque. New York, NY: Springer-Verlag; 1989:69-92.
29.
Schwartz SM, Heimark RL, Majesky MW.
Developmental mechanisms underlying pathology of
arteries. Physiol Rev. 1990;70:1177-1209.
30.
Joly GA, Schini VB, Vanhoutte PM. Balloon
injury and interleukin-1 beta induce nitric oxide synthase activity in
rat carotid arteries. Circ Res. 1992;71:331-338.
31. Printseva O, Peclo MM, Gown AM. Various cell types in human atherosclerotic lesions express ICAM-1: further immunocytochemical and immunochemical studies employing monoclonal antibody 10F3. Am J Pathol. 1992;140:889-896. [Abstract]
32. Poston RN, Haskard DO, Coucher JR, Gall NP, Johnson-Tidey RR. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol. 1992;140:665-673. [Abstract]
33.
Clausell N, Molossi S, Sett S, Rabinovitch
M. In vivo blockade of tumor necrosis factor-alpha in
cholesterol-fed rabbits after cardiac transplant
inhibits acute coronary artery neointimal
formation. Circulation. 1994;89:2768-2779.
34. Minick CR, Murphy GE. Experimental induction of arteriosclerosis by the synergy of allergic injury to arteries and lipid-rich diet, II: effect of repeatedly injected foreign protein in rabbits fed a lipid-rich, cholesterol-poor diet. Am J Pathol. 1973;73:265-300.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
H. Murayama, M. Takahashi, M. Takamoto, Y. Shiba, H. Ise, J. Koyama, Y.-i. Tagawa, Y. Iwakura, and U. Ikeda Deficiency of tumour necrosis factor-{alpha} and interferon-{gamma} in bone marrow cells synergistically inhibits neointimal formation following vascular injury Cardiovasc Res, November 1, 2008; 80(2): 175 - 180. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R. Ferreri Estrogen-TNF interactions and vascular inflammation Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2566 - H2569. [Full Text] [PDF] |
||||
![]() |
J.-P. Lin, C. J. O'Donnell, J. P. Schwaiger, L. A. Cupples, A. Lingenhel, S. C. Hunt, S. Yang, and F. Kronenberg Association Between the UGT1A1*28 Allele, Bilirubin Levels, and Coronary Heart Disease in the Framingham Heart Study Circulation, October 3, 2006; 114(14): 1476 - 1481. [Abstract] [Full Text] [PDF] |
||||
![]() |
Md. R. Abid, K. Yano, S. Guo, V. I. Patel, G. Shrikhande, K. C. Spokes, C. Ferran, and W. C. Aird Forkhead Transcription Factors Inhibit Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia J. Biol. Chem., August 19, 2005; 280(33): 29864 - 29873. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Fernando, L. P. Fernando, Y. Fukuda, and A. P. Kaplan Assembly, activation, and signaling by kinin-forming proteins on human vascular smooth muscle cells Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H251 - H257. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Tang, A. Dhirapong, A. P. Yabes, and R. H. Weiss TNF-{alpha}-mediated apoptosis in vascular smooth muscle cells requires p73 Am J Physiol Cell Physiol, July 1, 2005; 289(1): C199 - C206. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. C. Browner, H. Sellak, and T. M. Lincoln Downregulation of cGMP-dependent protein kinase expression by inflammatory cytokines in vascular smooth muscle cells Am J Physiol Cell Physiol, July 1, 2004; 287(1): C88 - C96. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-J. Park, H.-S. Kim, H.-M. Yang, K.-W. Park, S.-W. Youn, S.-I. Jeon, D.-H. Kim, B.-K. Koo, I.-H. Chae, D.-J. Choi, et al. Thalidomide as a Potent Inhibitor of Neointimal Hyperplasia After Balloon Injury in Rat Carotid Artery Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 885 - 891. [Abstract] [Full Text] |
||||
![]() |
M. Sugano, K. Tsuchida, and N. Makino Intramuscular Gene Transfer of Soluble Tumor Necrosis Factor-{alpha} Receptor 1 Activates Vascular Endothelial Growth Factor Receptor and Accelerates Angiogenesis in a Rat Model of Hindlimb Ischemia Circulation, February 17, 2004; 109(6): 797 - 802. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ling, A. Dai, R. J. Dilley, M. Jones, E. Simpson, P. A. Komesaroff, and K. Sudhir Endogenous Estrogen Deficiency Reduces Proliferation and Enhances Apoptosis-Related Death in Vascular Smooth Muscle Cells: Insights From the Aromatase-Knockout Mouse Circulation, February 3, 2004; 109(4): 537 - 543. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. D. I. Anderson, D. Rahmutula, and D. G. Gardner Tumor Necrosis Factor-{alpha} Inhibits Endothelial Nitric-oxide Synthase Gene Promoter Activity in Bovine Aortic Endothelial Cells J. Biol. Chem., January 9, 2004; 279(2): 963 - 969. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Chen, C. Capps, J. T. Willerson, and P. Zoldhelyi E2F-1 Regulates Nuclear Factor-{kappa}B Activity and Cell Adhesion: Potential Antiinflammatory Activity of the Transcription Factor E2F-1 Circulation, November 19, 2002; 106(21): 2707 - 2713. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kishore, I. Spyridopoulos, C. Luedemann, and D. W. Losordo Functionally Novel Tumor Necrosis Factor-{alpha}-Modulated CHR-Binding Protein Mediates Cyclin A Transcriptional Repression in Vascular Endothelial Cells Circ. Res., August 23, 2002; 91(4): 307 - 314. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Zimmerman, C. H. Selzman, L. L. Reznikov, S. A. Miller, C. D. Raeburn, J. Emmick, X. Meng, and A. H. Harken Lack of TNF-alpha attenuates intimal hyperplasia after mouse carotid artery injury Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2002; 283(2): R505 - R512. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Niemann-Jonsson, M. P.S. Ares, Z.-Q. Yan, D.-X. Bu, G. N. Fredrikson, L. Branen, I. Porn-Ares, A. H. Nilsson, and J. Nilsson Increased Rate of Apoptosis in Intimal Arterial Smooth Muscle Cells Through Endogenous Activation of TNF Receptors Arterioscler. Thromb. Vasc. Biol., December 1, 2001; 21(12): 1909 - 1914. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Chandrasekar, S. Nattel, and J.-F. Tanguay Coronary artery endothelial protection after local delivery of 17{beta}-estradiol during balloon angioplasty in a porcine model: a potential new pharmacologic approach to improve endothelial function J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1570 - 1576. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Krasinski, I. Spyridopoulos, M. Kearney, and D. W. Losordo In Vivo Blockade of Tumor Necrosis Factor-{alpha} Accelerates Functional Endothelial Recovery After Balloon Angioplasty Circulation, October 9, 2001; 104(15): 1754 - 1756. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Rectenwald, L. L. Moldawer, T. S. Huber, J. M. Seeger, and C. K. Ozaki Direct Evidence for Cytokine Involvement in Neointimal Hyperplasia Circulation, October 3, 2000; 102(14): 1697 - 1702. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. G. Anderson, N. J. Boerth, M. Liu, D. B. McNamara, T. L. Cornwell, and T. M. Lincoln Cyclic GMP-Dependent Protein Kinase Expression in Coronary Arterial Smooth Muscle in Response to Balloon Catheter Injury Arterioscler. Thromb. Vasc. Biol., October 1, 2000; 20(10): 2192 - 2197. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Niemann-Jonsson, P. Dimayuga, S. Jovinge, F. Calara, M. P. S. Ares, G. N. Fredrikson, and J. Nilsson Accumulation of LDL in Rat Arteries Is Associated With Activation of Tumor Necrosis Factor-{alpha} Expression Arterioscler. Thromb. Vasc. Biol., October 1, 2000; 20(10): 2205 - 2211. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Miller Jr AIF-1 in the Activated Smooth Muscle Cell : Spectator or Participant? Arterioscler. Thromb. Vasc. Biol., July 1, 2000; 20(7): 1701 - 1703. [Full Text] [PDF] |
||||
![]() |
W. Young, K. Mahboubi, A. Haider, I. Li, and N. R. Ferreri Cyclooxygenase-2 Is Required for Tumor Necrosis Factor-{alpha}- and Angiotensin II-Mediated Proliferation of Vascular Smooth Muscle Cells Circ. Res., April 28, 2000; 86(8): 906 - 914. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. D. Adams, J. M. Lemire, and S. M. Schwartz A Systematic Analysis of 40 Random Genes in Cultured Vascular Smooth Muscle Subtypes Reveals a Heterogeneity of Gene Expression and Identifies the Tight Junction Gene Zonula Occludens 2 as a Marker of Epithelioid "Pup" Smooth Muscle Cells and a Participant in Carotid Neointimal Formation Arterioscler. Thromb. Vasc. Biol., November 1, 1999; 19(11): 2600 - 2608. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Li, B. Yang, and J. L. Mehta Tumor necrosis factor-{alpha} enhances hypoxia-reoxygenation-mediated apoptosis in cultured human coronary artery endothelial cells: critical role of protein kinase C Cardiovasc Res, June 1, 1999; 42(3): 805 - 813. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Spyridopoulos, N. Principe, K. L. Krasinski, S.-h. Xu, M. Kearney, M. Magner, J. M. Isner, and D. W. Losordo Restoration of E2F Expression Rescues Vascular Endothelial Cells From Tumor Necrosis Factor-{alpha}–Induced Apoptosis Circulation, December 22, 1998; 98(25): 2883 - 2890. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kume, T. Murase, H. Moriwaki, T. Aoyama, T. Sawamura, T. Masaki, and T. Kita Inducible Expression of Lectin-like Oxidized LDL Receptor-1 in Vascular Endothelial Cells Circ. Res., August 10, 1998; 83(3): 322 - 327. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-S. Lee, M. K. Jain, B. M. Arkonac, D. Zhang, S.-Y. Shaw, S. Kashiki, K. Maemura, S.-L. Lee, N. K. Hollenberg, M.-E. Lee, et al. Thy-1, a Novel Marker for Angiogenesis Upregulated by Inflammatory Cytokines Circ. Res., May 4, 1998; 82(8): 845 - 851. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Spyridopoulos, A. B. Sullivan, M. Kearney, J. M. Isner, and D. W. Losordo Estrogen-Receptor–Mediated Inhibition of Human Endothelial Cell Apoptosis : Estradiol as a Survival Factor Circulation, March 18, 1997; 95(6): 1505 - 1514. [Abstract] [Full Text] |
||||
![]() |
S. Jovinge, A. Hultgardh-Nilsson, J. Regnstrom, and J. Nilsson Tumor Necrosis Factor-{alpha} Activates Smooth Muscle Cell Migration in Culture and Is Expressed in the Balloon-Injured Rat Aorta Arterioscler. Thromb. Vasc. Biol., March 1, 1997; 17(3): 490 - 497. [Abstract] [Full Text] |
||||
![]() |
R. Kranzhofer, S. K. Clinton, K. Ishii, S. R. Coughlin, J. W. Fenton, and P. Libby Thrombin Potently Stimulates Cytokine Production in Human Vascular Smooth Muscle Cells but Not in Mononuclear Phagocytes Circ. Res., August 1, 1996; 79(2): 286 - 294. [Abstract] [Full Text] |
||||
![]() |
S. Goetze, U. Kintscher, H. Kawano, Y. Kawano, S. Wakino, E. Fleck, W. A. Hsueh, and R. E. Law Tumor Necrosis Factor alpha Inhibits Insulin-induced Mitogenic Signaling in Vascular Smooth Muscle Cells J. Biol. Chem., June 9, 2000; 275(24): 18279 - 18283. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |